Sign in Subscribe
United States. Securities and Exchange Commission

Comera Life Sciences Holdings, Inc. Files FORM 8-K with SEC: Disclosure of Regulation FD

Strategic Insights

— 1 min read

Comera Life Sciences Holdings, Inc., a Delaware-based biotech company, has filed a current report (FORM 8-K) with the U.S. Securities and Exchange Commission (SEC) on October 2, 2023. The report provides details on the company's recent activities, including a private placement of common stock and warrants, and the redemption of Series A Convertible Perpetual Preferred Stock.

As previously disclosed, Comera Life Sciences notified Maxim Group LLC, the sole holder of Series A Convertible Perpetual Preferred Stock, that the issuance of common stock and warrants in a private placement on September 11, 2023, constituted a Qualifying Financing Event. The Company determined the Qualifying Financing Proceeds to be equal to $453,000. Maxim elected to have the Company use these proceeds to redeem 409.47 shares of the Series A Preferred Stock on September 19, 2023.

Key Takeaways:

  • Comera Life Sciences Holdings, Inc. filed FORM 8-K with the SEC on October 2, 2023, to disclose Regulation FD details.
  • The Company notified Maxim Group LLC that the private placement of common stock and warrants on September 11, 2023, was a Qualifying Financing Event, triggering the redemption of Series A Convertible Perpetual Preferred Stock.
  • The Qualifying Financing Proceeds, as determined by the Company, were equal to $453,000.
  • Maxim elected to have the Company use these proceeds to redeem 409.47 shares of the Series A Preferred Stock on September 19, 2023.
  • The Company is obligated to provide written notice to Series A Preferred Stock holders and make a public announcement of the aggregate Qualifying Financing Proceeds within three trading days of a Series A Quarterly Dividend Payment Date.
  • As of October 1, 2023, the aggregate amount of Qualifying Financing Proceeds is nil.

Statistics:

  • $453,000: The Qualifying Financing Proceeds, as determined by the Company.
  • 409.47: The number of shares of Series A Preferred Stock redeemed on September 19, 2023.
  • September 11, 2023: The date of the private placement of common stock and warrants.
  • September 19, 2023: The date on which 409.47 shares of Series A Preferred Stock were redeemed.
  • October 1, 2023: The date by which the Company was obligated to provide written notice to Series A Preferred Stock holders and make a public announcement of the aggregate Qualifying Financing Proceeds.

Sources:

  • United States Securities and Exchange Commission, "Comera Life Sciences Holdings, Inc. (Exact name of registrant as specified in its charter)" (Form 8-K), October 2, 2023.

Read more